Virax Biolabs CEO shares fiscal 2026 results and Fosun agreement
Cash at $6.4M, total assets $8.3M, and recent $3.3M financing strengthen balance sheet while Nasdaq compliance regained
See the latest news and media coverage for Virax Biolabs. We track all announcements, press releases, and industry mentions in real time, all in one place.
Immunology research and diagnostic company
viraxbiolabs.comLast updated
In short: Virax Biolabs expanded its China reach with three ImmuneSelect distributor agreements.
Cash at $6.4M, total assets $8.3M, and recent $3.3M financing strengthen balance sheet while Nasdaq compliance regained
Cash at March 31, 2026 totals $6,438,909, against accounts payable and accrued liabilities of $309,463, with comparative 2025 figures shown in multiple currencies.
The consolidation aims to regain Nasdaq compliance and will be effective June 26, 2026.
The offering of 12.5M shares at $0.40 each will provide working capital. H.C. Wainwright acted as placement agent.
Three new distributor agreements build on initial China sales and extend the Company's distributor-led commercial strategy. LONDON, Oct. 29, 2026 /PRNewswire/ -- Virax Biolabs Gro...
Virax Biolabs Group Limited was implementing a restructuring of its management structure aimed at streamlining the organization and reducing operating costs, all...
Virax Biolabs Group Limited (the Company) was implementing a restructuring of its senior management structure designed to streamline the organization and reduce operating expenditure whilst...
Virax Biolabs enters exclusive multi-country commercial supply agreement with Fosun Diagnostics: London Saturday, July 11, 2026, 11:00 Hrs [IST] Virax Biolabs Group Limited, a bio...
Track Virax Biolabs and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Virax Biolabs and other trending companies.